Drug resistance study for tuberculosis infection
Part of Infections clinical trials.
This trial looks at how tuberculosis bacteria might resist treatment. It studies people who test positive for TB using a GeneXpert test, both in the lungs and other body parts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have tested positive for tuberculosis on a GeneXpert test
- You must be at least 12 years old
- TB infection can be in your lungs or elsewhere in your body
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people newly diagnosed with tuberculosis (TB) and looks at how TB bacteria can become resistant to multiple drugs. It will help doctors understand which treatments work best for new TB patients.
This trial tests whether using results from a detailed sputum (phlegm) test to tailor treatment improves outcomes in people with drug-resistant (rifampicin-resistant) pulmonary TB. It may help you get the most appropriate regimen based on your specific test results.
This study looks at the types of drug-resistant tuberculosis (TB) bacteria spreading in Central Africa. By examining sputum samples from people with TB, researchers hope to better understand how resistant strains are transmitted, which can help improve treatment.
This study compares a new, fast test (GeneXpert) to standard lab methods for finding TB bacteria and checking if they are resistant to a key antibiotic (rifampicin). It is open to adults who are suspected of having TB for the first time.
This study uses next-generation gene testing to help manage active drug-resistant tuberculosis. It may help doctors choose the most appropriate treatment by better identifying the TB’s drug resistance.
This study tracks people with tuberculosis that is mainly outside the lungs (extrapulmonary TB). It collects medical information and samples to better understand the disease and improve care. If you have this type of TB, joining could help advance knowledge and treatment.
Hear when a new Pulmonary and Extra- Pulmonary Tuberculosis (TB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.